Amendments to the claims:

This listing of claims will replace all prior versions and listings, of claims, in the application.

Listing of Claims:

WHAT IS CLAIMED IS:

1. (currently amended) A compound of Formula (I):



Formula I

wherein:

Ar is selected from the group consisting of aryl, pyridinyl, quinolinyl and isoquinolinyl ~~and heteroaryl~~;

m is an integer from 0 to 2, n is an integer from 0 to 2, with the proviso that m and n are not both simultaneously 0;

R_1 is selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{2-8}alkenyl, aryl, aryl(C_{1-8})alkyl, ~~heteroaryl(C_{1-8})alkyl,~~ amino(C_{1-8})alkyl, C_{1-8}alkyl-NH-(C_{1-8})alkyl, (C_{1-8}alkyl)$_2$-N-(C_{1-8})alkyl, hydroxy(C_{1-8})alkyl and C_{1-8}alkoxy(C_{1-8})alkyl;

R_2 and R_3 are optionally present and independently selected from C_{1-8}alkyl;

R_4 is one to three substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, C_{3-8}cycloalkyl, aryl(C_{1-8})alkyl,

C_{1-8}alkoxy, aryloxy, aryl(C_{1-8})alkyloxy, C_{1-8}alkylthio, trifluoro(C_{1-8})alkyl, trifluoro(C_{1-8})alkoxy, amino, -NH(C_{1-8})alkyl, -N[(C_{1-8})alkyl]$_2$, -NH(aryl), -N(aryl)$_2$, -NH(C_{1-8})alkylaryl, -N[(C_{1-8})alkylaryl]$_2$, -CO_2H, -CO_2(C_{1-8})alkyl, -CO_2(aryl), -C(O)NH_2, -C(O)NH(C_{1-8})alkyl, -C(O)N[(C_{1-8})alkyl]$_2$, -NHC(O)(C_{1-8})alkyl, -SO_2H, -SO_2(C_{1-8})alkyl, -S(O_2)NH_2, -S(O_2)NH(C_{1-8})alkyl, -S(O_2)N[(C_{1-8})alkyl]$_2$, -C(O)(C_{1-8})alkyl, -C(O)aryl, -C(O)(C_{1-8})alkylaryl, aryl, ~~heteroaryl, heterocyclyl,~~ halogen, hydroxy, cyano, and nitro;

X is selected from the group consisting of O and S;

Z is N(R_5)(R_6) or is a 5- or 6-membered saturated, monocyclic~~, heterocyclic~~ ring~~, wherein said heterocyclic ring contains one nitrogen member which is the point of attachment, optionally contains one additional heteroatom member of oxygen, sulfur or nitrogen and optionally contains a double bond between two ring members~~;

R_5 and R_6 are independently selected from the group consisting of hydrogen, C_{1-8}alkyl, hydroxy(C_{1-8})alkyl, C_{2-8}alkenyl, C_{3-8}cycloalkyl, aryl and aryl(C_{1-8})alkyl, wherein said cycloalkyl, aryl and the aryl portion of aryl(C_{1-8})alkyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-8}alkyl, C_{2-8}alkenyl, C_{1-8}alkoxy, trifluoro(C_{1-8})alkyl, trifluoro(C_{1-8})alkoxy, C_{3-8}cycloalkyl and halogen; and,

the moiety –C(X)Z is attached on the phenyl at the 3 or 4 position;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

2. (Currently amended) The compound of claim 1 wherein Ar is phenyl, naphthyl, ~~furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, isozazolyl, isothiazolyl, indolyl, indazolyl, benzo[b]thienyl,~~ quinolinyl, isoquinolinyl, ~~quinazolinyl, pyrrolyl, imidazolyl, pyrazolyl,~~ or pyridinyl~~, pyrimidinyl, pyrazinyl, or pyridazinyl~~.

3. (Original) The compound of claim 1 wherein Ar is phenyl or pyridinyl.

4. (Original) The compound of claim 1 wherein m is an integer from 0 to 1, n is an integer from 0 to 1, with the proviso that m and n are not both simultaneously 0.

5. (Currently amended) The compound of claim 1 R_1 is selected from the group consisting of hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, aryl, aryl(C_{1-4})alkyl, ~~heteroaryl(C_{1-4})alkyl,~~ NH_2(C_{1-4})alkyl, C_{1-4}alkyl-NH-(C_{1-4})alkyl, (C_{1-4}alkyl)$_2$-N-(C_{1-4})alkyl, hydroxy(C_{1-4})alkyl and C_{1-4}alkoxy(C_{1-4})alkyl.

6. (Original) The compound of claim 1 wherein R_1 is selected from the group consisting of hydrogen, C_{1-4}alkyl and C_{2-4}alkenyl.

7. (Original) The compound of claim 1 wherein R_1 is selected from the group consisting of hydrogen, *n*-propyl and allyl.

8. (Original) The compound of claim 1 wherein R_2 and R_3 are optionally present and independently selected from C_{1-4}alkyl.

9. (Original) The compound of claim 1 wherein R_2 and R_3 are not present.

10. (Original) The compound of claim 1 wherein R_4 is one to three substituents.

11. (Original) The compound of claim 1 wherein R_4 is independently selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{1-8}alkoxy, trifluoro(C_{1-8})alkyl, trifluoro(C_{1-8})alkoxy, cyano, halogen, hydroxy and nitro.

12. (Original) The compound of claim 1 wherein R_4 is independently selected from the group consisting of hydrogen, C_{1-8}alkoxy, trifluoro(C_{1-8})alkyl, hydroxy and halogen.

13. (Original) The compound of claim 1 wherein R_4 is independently selected from the group consisting of hydrogen, methoxy, trifluoromethyl, hydroxy, fluoro and chloro.

14. (Original) The compound of claim 1 wherein X is O.

15. (Original) The compound of claim 1 wherein Z is $N(R_5)(R_6)$.

16. (Original) The compound of claim 1 wherein R_5 and R_6 are independently selected from the group consisting of hydrogen, C_{1-4}alkyl, hydroxy(C_{1-4})alkyl, C_{2-4}alkenyl, C_{3-8}cycloalkyl, aryl and aryl(C_{1-4})alkyl, wherein said cycloalkyl, aryl and the aryl portion of aryl(C_{1-8})alkyl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-4}alkyl, C_{2-4}alkenyl, C_{1-4}alkoxy, C_{3-8}cycloalkyl, halogen, trifluoro(C_{1-4})alkyl and trifluoro(C_{1-4})alkoxy.

17. (Original) The compound of claim 1 wherein R_5 and R_6 are independently selected from the group consisting of hydrogen and C_{1-4}alkyl.

18. (Original) The compound of claim 1 wherein R_5 and R_6 independently selected from the group consisting of hydrogen, methyl and ethyl.

19. (Currently amended)The compound of claim 1 wherein the compound of Formula (I) is selected from Formula (Ia):



wherein

Ar is selected from the group consisting of aryl, pyridinyl, quinolinyl and isoquinolinyl ~~and heteroaryl~~;

R_1 is selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{2-8}alkenyl, aryl, aryl(C_{1-8})alkyl, ~~heteroaryl(C_{1-8})alkyl,~~ amino(C_{1-8})alkyl, C_{1-8}alkyl-NH-(C_{1-8})alkyl, (C_{1-8}alkyl)$_2$-N-(C_{1-8})alkyl, hydroxy(C_{1-8})alkyl and C_{1-8}alkoxy(C_{1-8})alkyl;

R_4 is one to three substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, C_{3-8}cycloalkyl, aryl(C_{1-8})alkyl, C_{1-8}alkoxy, aryloxy, aryl(C_{1-8})alkyloxy, C_{1-8}alkylthio, trifluoro(C_{1-8})alkyl, trifluoro(C_{1-8})alkoxy, amino, -NH(C_{1-8})alkyl, -N[(C_{1-8})alkyl]$_2$, -NH(aryl), -N(aryl)$_2$, -NH(C_{1-8})alkylaryl, -N[(C_{1-8})alkylaryl]$_2$, -CO_2H, -CO_2(C_{1-8})alkyl, -CO_2(aryl), -C(O)NH_2, -C(O)NH(C_{1-8})alkyl, -C(O)N[(C_{1-8})alkyl]$_2$, -NHC(O)(C_{1-8})alkyl, -SO_2H, -SO_2(C_{1-8})alkyl, -S(O_2)NH_2, -S(O_2)NH(C_{1-8})alkyl, -S(O_2)N[(C_{1-8})alkyl]$_2$, -C(O)(C_{1-8})alkyl, -C(O)aryl, -C(O)(C_{1-8})alkylaryl, aryl, ~~heteroaryl, heterocyclyl,~~ halogen, hydroxy, cyano, and nitro;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

20. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from Formula (Ia):



Wherein Ar, R_1 and R_4 are dependently selected from:

R_1	Ar	R_4
n-Pr	phenyl	3-methoxy
n-Pr	phenyl	3-hydroxy
n-Pr	phenyl	3-chloro
n-Pr	phenyl	2-methoxy
n-Pr	phenyl	2-hydroxy
n-Pr	phenyl	3-fluoro
n-Pr	phenyl	H
H	phenyl	H
allyl	phenyl	H
i-Pr	phenyl	H
N, *N*-dimethyl aminopropyl	phenyl	H
n-Pr	phenyl	4-methoxy
n-Pr	3-pyridinyl	H
Me	phenyl	H
n-Pr	phenyl	3-trifluoromethyl
n-Pr	phenyl	4-fluoro

and pharmaceutically acceptable salts thereof.

21. (Currently amended) The compound of claim 1 wherein the compound of Formula (I) is selected from Formula (Ib):



wherein

Ar is selected from the group consisting of aryl, pyridinyl, quinolinyl and isoquinolinyl ~~and heteroaryl~~;

R_4 is one to three substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, C_{3-8}cycloalkyl, aryl(C_{1-8})alkyl, C_{1-8}alkoxy, aryloxy, aryl(C_{1-8})alkyloxy, C_{1-8}alkylthio, trifluoro(C_{1-8})alkyl, trifluoro(C_{1-8})alkoxy, amino, -NH(C_{1-8})alkyl, -N[(C_{1-8})alkyl]$_2$, -NH(aryl), -N(aryl)$_2$, -NH(C_{1-8})alkylaryl, -N[(C_{1-8})alkylaryl]$_2$, -CO_2H, -CO_2(C_{1-8})alkyl, -CO_2(aryl), -C(O)NH_2, -C(O)NH(C_{1-8})alkyl, -C(O)N[(C_{1-8})alkyl]$_2$, -NHC(O)(C_{1-8})alkyl, -SO_2H, -SO_2(C_{1-8})alkyl, -S(O_2)NH_2, -S(O_2)NH(C_{1-8})alkyl, -S(O_2)N[(C_{1-8})alkyl]$_2$, -C(O)(C_{1-8})alkyl, -C(O)aryl, -C(O)(C_{1-8})alkylaryl, aryl, ~~heteroaryl, heterocyclyl,~~ halogen, hydroxy, cyano, and nitro;

the moiety –C(X)Z is attached on the phenyl at the 3 or 4 position;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

22. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from Formula (Ib):



Formula (Ib)

Wherein Ar, R_4 and the position for $-C(O)(NEt_2)$ is selected from:

Ar	R_4	Amide Substitution
phenyl	3-methoxy	4
phenyl	3-methoxy	3
phenyl	3-hydroxy	3
phenyl	H	3
phenyl	3-fluoro	3

and pharmaceutically acceptable salts thereof.

23. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

24. (Original) A method for preparing a pharmaceutical composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

25. (Original) A method for treating a disorder modulated by the δ-opioid receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

26. (Original) The method of claim 25 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/day to about 12,000 mg/day.

27. (Original) The method of claim 25 wherein the disorder is pain modulated by a therapeutically effective amount of a compound of claim 1.

28. (Original) The method of claim 25 wherein the disorder is selected from the group consisting of immune disorders, inflammation, neurological conditions, psychiatric conditions, drug abuse, alcohol abuse, gastritis, diarrhea,

cardiovascular disorders and respiratory disorders modulated by a therapeutically effective amount of a compound of claim 1.

29. (Original) The method of claim 25 further comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 23.

30. (Original) The method of claim 25 wherein the therapeutically effective amount of the pharmaceutical composition of claim 23 is from about 0.001 mg/day to about 12,000 mg/day.